<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03864419</url>
  </required_header>
  <id_info>
    <org_study_id>RG1001799</org_study_id>
    <secondary_id>U028</secondary_id>
    <secondary_id>NCI-2019-01493</secondary_id>
    <secondary_id>10040</secondary_id>
    <nct_id>NCT03864419</nct_id>
  </id_info>
  <brief_title>Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda</brief_title>
  <official_title>A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in Uganda</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies how well rituximab hyaluronidase and combination chemotherapy work&#xD;
      in treating patients in Uganda with Burkitt lymphoma, diffuse large B-cell lymphoma, or&#xD;
      Kaposi sarcoma herpesvirus associated multicentric Castleman disease. Rituximab hyaluronidase&#xD;
      is a combination of rituximab and hyaluronidase. Rituximab binds to a molecule called CD20,&#xD;
      which is found on B cells (a type of white blood cell) and some types of cancer cells. This&#xD;
      may help the immune system kill cancer cells. Hyaluronidase allows rituximab to be given by&#xD;
      injection under the skin. Giving rituximab and hyaluronidase by injection under the skin is&#xD;
      faster than giving rituximab alone by infusion into the blood. Drugs used in chemotherapy,&#xD;
      such as cyclophosphamide, vincristine, methotrexate, etoposide, doxorubicin, and prednisone&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells, by&#xD;
      stopping them from dividing, or by stopping them from spreading. While rituximab has a clear&#xD;
      survival benefit in patients within developed countries, differences in supportive care and&#xD;
      infectious co-morbidities require special attention. Giving rituximab hyaluronidase alone or&#xD;
      in combination with chemotherapy may work better in treating patients with Burkitt lymphoma,&#xD;
      diffuse large B-cell lymphoma, or Kaposi sarcoma herpesvirus associated multicentric&#xD;
      Castleman disease compared to chemotherapy alone in Uganda.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      Open-label Phase I study characterizing the safety, tolerability, and activity of&#xD;
      subcutaneous rituximab hyaluronidase (sqR) alone (KSHV-MCD), or combined with local standard&#xD;
      of care chemotherapy (BL or DLBCL), in 2 age-based cohorts of patients:&#xD;
&#xD;
        1. Cohort 1: Age &gt;= 15&#xD;
&#xD;
        2. Cohort 2: Age: 2-14&#xD;
&#xD;
      sqR dose for Cohort 1 (adults) will be 1400 mg (flat dose); sqR dose for Cohort 2&#xD;
      (pediatrics) will depend on patient weight: &gt;= 35 kg: 1400 mg, &lt; 35 kg: 700 mg. For all&#xD;
      participants, sqR will be administered with local standard of care chemotherapy (BL, DLBCL)&#xD;
      or alone (KSHV-MCD), and supportive care.&#xD;
&#xD;
      Each cohort comprises two Therapy Groups. Therapy Group 1: up to 6 participants and will&#xD;
      receive the first cycle of rituximab IV, and subsequent cycles as flat-dose sqR. Therapy&#xD;
      Group 2: up to 12 participants and will receive flat-dose sqR for all cycles.&#xD;
&#xD;
      Disease-specific chemotherapy to be administered with rituximab hyaluronidase include:&#xD;
&#xD;
      PEDIATRIC BURKITT LYMPHOMA (BL): cyclophosphamide, vincristine and prednisone followed by 6&#xD;
      cycles of cyclophosphamide, vincristine, and methotrexate (COP-COM).&#xD;
&#xD;
      DLBCL: 6 cycles of cyclophosphamide, doxorubicin, vincristine and prednisone PO on days 1-5&#xD;
      of cycle 1 (CHOP).&#xD;
&#xD;
      ADULT BL: 6 cycles modified dose: etoposide, doxorubicin, vincristine, cyclophosphamide and&#xD;
      prednisone PO on days 1-5 (adjusted EPOCH).&#xD;
&#xD;
      KSHV-MCD: Rituximab or rituximab hyaluronidase SC on days 1, 8, 15, and 22.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days, 3, 6, 9 and 12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">May 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 4, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Common Terminology Criteria for Adverse Events version 5.0 including unanticipated problems and grade 3-5 adverse events (AEs) at least probably related to subcutaneous rituximab hyaluronidase (sqR) administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants that result in sufficient pharmacodynamic criteria</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Pharmacodynamic criteria is a Ctrough level above 25 ug/ml in children and adolescents after the first subcutaneous dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving a repose of complete response (CR)</measure>
    <time_frame>1 year</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) criteria CR: complete disappearance of all target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Kaplan-Meier estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Kaplan-Meier estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Kaplan-Meier estimate</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Burkitt Lymphoma</condition>
  <condition>KSHV-associated Multicentric Castleman Disease</condition>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohort I (pediatric BL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV and vincristine IV on day 1, and prednisone IV or PO on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients then receive rituximab IV or rituximab hyaluronidase SC, cyclophosphamide IV, vincristine IV, and methotrexate IV on day 1. Cycles repeat every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II (DLBCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab IV or rituximab and hyaluronidase human SC, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1, and prednisone PO on days 1-5 of cycle 1. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort III (Adult BL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab IV or rituximab and hyaluronidase human SC in day 1, etoposide IV, doxorubicin IV, and vincristine IV on days 1-4. Patients also receive cyclophosphamide IV on day 5 and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort IV (MCD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab IV or rituximab and hyaluronidase human SC on days 1, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab and Hyaluronidase Human</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Cohort I (pediatric BL)</arm_group_label>
    <arm_group_label>Cohort II (DLBCL)</arm_group_label>
    <arm_group_label>Cohort III (Adult BL)</arm_group_label>
    <arm_group_label>Cohort IV (MCD)</arm_group_label>
    <other_name>Rituxan Hycela</other_name>
    <other_name>Rituximab Plus Hyaluronidase</other_name>
    <other_name>Rituximab/Hyaluronidase</other_name>
    <other_name>Rituximab/Hyaluronidase Human</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort I (pediatric BL)</arm_group_label>
    <arm_group_label>Cohort II (DLBCL)</arm_group_label>
    <arm_group_label>Cohort III (Adult BL)</arm_group_label>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort I (pediatric BL)</arm_group_label>
    <arm_group_label>Cohort II (DLBCL)</arm_group_label>
    <arm_group_label>Cohort III (Adult BL)</arm_group_label>
    <other_name>LEUROCRISTINE</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincrystine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort I (pediatric BL)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort II (DLBCL)</arm_group_label>
    <arm_group_label>Cohort III (Adult BL)</arm_group_label>
    <other_name>Hydroxyl Daunorubicin</other_name>
    <other_name>Hydroxyldaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort II (DLBCL)</arm_group_label>
    <arm_group_label>Cohort III (Adult BL)</arm_group_label>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Cohort II (DLBCL)</arm_group_label>
    <arm_group_label>Cohort III (Adult BL)</arm_group_label>
    <other_name>Deltacortene</other_name>
    <other_name>Decorton</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Econosone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort II (DLBCL)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Vepesid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort I (pediatric BL)</arm_group_label>
    <arm_group_label>Cohort II (DLBCL)</arm_group_label>
    <arm_group_label>Cohort III (Adult BL)</arm_group_label>
    <arm_group_label>Cohort IV (MCD)</arm_group_label>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab ABBS</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar JHL1101</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SIBP-02</other_name>
    <other_name>rituximab biosimilar TQB2303</other_name>
    <other_name>RTXM83</other_name>
    <other_name>Truxima</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histology and immunohistochemistry (CD20+) confirmed Burkitt lymphoma (BL), diffuse&#xD;
             large B-cell lymphoma (DLBCL), or histology confirmed KSHV-associated multicentric&#xD;
             Castleman disease with elevated blood KSHV viral load&#xD;
&#xD;
          -  Cohort 1: Age should be equal to or greater than 15&#xD;
&#xD;
          -  Cohort 2: Age: 2-15&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Able to provide informed consent (adults) or assent (children &lt; 18 years) in English&#xD;
             or Luganda&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-infected patients eligible if meet the following&#xD;
             criteria:&#xD;
&#xD;
               -  CD4+ T-cell count &gt; 200 cells/uL&#xD;
&#xD;
               -  HIV treatable with effective antiretroviral therapy that does not include agents&#xD;
                  with known significant drug-drug interactions with accompanying chemotherapy&#xD;
                  (ritonavir and cobicistat contraindicated)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous therapy for lymphoma or KSHV-multicentric Castleman disease (MCD)&#xD;
&#xD;
          -  History of hypersensitivity to rituximab&#xD;
&#xD;
          -  Pregnant or nursing women. Men or women may not participate unless they have agreed to&#xD;
             use effective contraception during treatment and for 12 months following completion of&#xD;
             therapy&#xD;
&#xD;
          -  Inadequate organ function, unless attributed to lymphoma or KSHV-MCD&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &gt; 2.5 times upper&#xD;
             limit of normal&#xD;
&#xD;
          -  Creatinine &gt; 2 times upper limit than normal or calculated creatinine clearance &lt; 60&#xD;
             mL/min&#xD;
&#xD;
          -  New York Heart Association (NYHA) cardiac failure class III or IV&#xD;
&#xD;
          -  Patients with clinically significant anemia-hemoglobin less than 10 g/dL&#xD;
&#xD;
          -  Central nervous system (CNS) masses consistent with lymphoma or untreated infection;&#xD;
             leptomeningeal disease will not be excluded&#xD;
&#xD;
          -  Patients with malignancy within 5 years, other than resected local skin cancer or&#xD;
             limited Kaposi sarcoma (KS) (no known pulmonary KS)&#xD;
&#xD;
          -  Patients with evidence of active infections including malaria and hepatitis B&#xD;
             (participants with hepatitis B virus [HBV] controlled on antivirals will not be&#xD;
             excluded)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manoj Menon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manoj Menon, MD</last_name>
    <phone>206.667.4636</phone>
    <email>mmenon@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCI-Fred Hutch Cancer Centre</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Asea</last_name>
      <phone>(256) 706915390</phone>
      <email>jasea@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Jackson Orem, MBChB, MMed, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henry Ddungu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joyce Balagadde Kambugu, MBChB, MMed, CMO Paed (SA)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Castleman Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

